Bilaketaren emaitzak - Jaume Capdevila

Findu emaitzak
  1. 1
    Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib

    Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib nork Jaume Capdevila, Neda Stjepanovic

    Argitaratua 2014
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  2. 2
    GEP–NETs UPDATE: Biotherapy for neuroendocrine tumours

    GEP–NETs UPDATE: Biotherapy for neuroendocrine tumours nork Teresa Alonso‐Gordoa, Jaume Capdevila, Enrique Grande

    Argitaratua 2014
    Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  3. 3
    Thyroid Cancer: Molecular Aspects and New Therapeutic Strategies

    Thyroid Cancer: Molecular Aspects and New Therapeutic Strategies nork Enrique Grande, Juan J. Díez, Carles Zafón, Jaume Capdevila

    Argitaratua 2012
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  4. 4
    Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer

    Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer nork Anubha Gupta, Barbara Jarząb, Jaume Capdevila, Robert Shumaker, Ziad Hussein

    Argitaratua 2016
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  5. 5
    What is the status of immunotherapy in thyroid neoplasms?

    What is the status of immunotherapy in thyroid neoplasms? nork Alejandro García‐Álvarez, Jorge Hernando, Ana Carmona-Alonso, Jaume Capdevila

    Argitaratua 2022
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  6. 6
    Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era

    Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era nork Jaume Capdevila, Ahmad Awada, Dagmar Führer‐Sakel, Sophie Leboulleux, Patrick Pauwels

    Argitaratua 2022
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  7. 7
    Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia

    Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia nork Rodrigo A. Toledo, Camilo Jiménez, Gustavo Armaiz-Peña, Carlota Arenillas, Jaume Capdevila, Patricia L. M. Dahia

    Argitaratua 2022
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  8. 8
    Cabozantinib for the treatment of solid tumors: a systematic review

    Cabozantinib for the treatment of solid tumors: a systematic review nork Pablo Maroto, Camillo Porta, Jaume Capdevila, Andrea B. Apolo, Santiago Viteri, Cristina Rodríguez‐Antona, Lidia Martín, Daniel Castellano

    Argitaratua 2022
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  9. 9
    Genomics Review of Selective <scp>RET</scp> Inhibitors Sensitivity in Thyroid Cancer Clinical Trials

    Genomics Review of Selective <scp>RET</scp> Inhibitors Sensitivity in Thyroid Cancer Clinical Trials nork Sara Gil‐Bernabé, Lucía García‐DeLaFuente, Alejandro García‐Álvarez, Ginesa García‐Rostán, Jaume Capdevila, Jorge Hernando

    Argitaratua 2025
    Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  10. 10
    Streptozotocin, 1982–2022: Forty Years from the FDA’s Approval to Treat Pancreatic Neuroendocrine Tumors

    Streptozotocin, 1982–2022: Forty Years from the FDA’s Approval to Treat Pancreatic Neuroendocrine Tumors nork Jaume Capdevila, Michel Ducreux, Rocio García‐Carbonero, Enrique Grande, Þorvarður R. Hálfdánarson, Anne Couvelard, Salvatore Tafuto, Staffan Welin, Vicente Valentí, Ramón Salazar

    Argitaratua 2022
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  11. 11
    Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies

    Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies nork Enrique Grande, Michael C. Kreißl, Sébastiano Filetti, Kate Newbold, Walter Reinisch, Caroline Robert, Martin Schlumberger, Lærke Kjær Tolstrup, José Luís Zamorano, Jaume Capdevila

    Argitaratua 2013
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  12. 12
    Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development

    Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in dev... nork Rocio García‐Carbonero, Roberto García‐Figueiras, Alberto Carmona‐Bayonas, Isabel Sevilla, Àlex Teulé, María Quindós, Enrique Grande, Jaume Capdevila, Javier Aller, Javier Arbizu, Paula Jiménez‐Fonseca

    Argitaratua 2015
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  13. 13
    Sorafenib in metastatic thyroid cancer

    Sorafenib in metastatic thyroid cancer nork Jaume Capdevila, L. Iglesias, Irene Halperín, Ángel Segura, Javier Martínez‐Trufero, María Ángeles Vaz Salgado, J. Corral, Gabriel Obiols, Enrique Grande, Juan J. Grau, Josep Tabernero

    Argitaratua 2012
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  14. 14
    Impact of Prior Chemotherapy Use on the Efficacy of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors

    Impact of Prior Chemotherapy Use on the Efficacy of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors nork Catherine Lombard‐Bohas, James C. Yao, Timothy J. Hobday, Eric Van Cutsem, Edward M. Wolin, Ashok Panneerselvam, Sotirios Stergiopoulos, Manisha H. Shah, Jaume Capdevila, Rodney F. Pommier

    Argitaratua 2014
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  15. 15
    Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results

    Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results nork Marianne Pavel, Jarosław B. Ćwikła, Catherine Lombard‐Bohas, Ivan Borbath, Tahir Shah, Ulrich F. Pape, Jaume Capdevila, Francesco Panzuto, Xuan-Mai Truong Thanh, Aude Houchard, Philippe Ruszniewski

    Argitaratua 2021
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  16. 16
    Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer

    Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer nork Bruce Robinson, Martin Schlumberger, Lori J. Wirth, Corina E. Dutcus, James Song, Matthew H. Taylor, Sung‐Bae Kim, Monika K. Krzyzanowska, Jaume Capdevila, Steven I. Sherman, Makoto Tahara

    Argitaratua 2016
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  17. 17
    Libretto-531: A Phase III Study of Selpercatinib in Multikinase Inhibitor-Naïve <i>RET</i> -Mutant Medullary Thyroid Cancer

    Libretto-531: A Phase III Study of Selpercatinib in Multikinase Inhibitor-Naïve <i>RET</i> -Mutant Medullary Thyroid Cancer nork Lori J. Wirth, Marcia S. Brose, Rossella Elisei, Jaume Capdevila, Ana O. Hoff, Mimi I. Hu, Makoto Tahara, Bruce Robinson, Ming Gao, Xia Meng, Patricia Maeda, Eric J. Sherman

    Argitaratua 2022
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  18. 18
    ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors

    ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors nork Massimo Falconi, Barbro Eriksson, Gregory Kaltsas, Detlef K. Bartsch, Jaume Capdevila, Martyn Caplin, Beata Kos‐Kudła, Dik J. Kwekkeboom, Guido Rindi, Günter Klöppel, Nicholas S. Reed, Réza Kianmanesh, Robert T. Jensen

    Argitaratua 2016
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  19. 19
    Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer

    Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer nork Garazi Serna, Fiorella Ruíz‐Pace, Jorge Hernando, Lidia Alonso, Roberta Fasani, Stefania Landolfi, Raquel Comas, José Jiménez, Elena Élez, Susan Bullman, Josep Tabernero, Jaume Capdevila, Rodrigo Dienstmann, Paolo Nucíforo

    Argitaratua 2020
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  20. 20
    A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors

    A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors nork Josep Tabernero, Luc Dirix, Patrick Schöffski, Andrés Cervantes, José A. López-Martín, Jaume Capdevila, Ludy van Beijsterveldt, Suso Platero, Brett M. Hall, Zhilong Yuan, R.E. Knoblauch, Sen Hong Zhuang

    Argitaratua 2011
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:

Bilaketa egiteko lanabesak: